linjc16/ctgov huggingface dataset:
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.

Detailed Description
-----------------
This will be a randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups. Patients will be stratified by clinical center and foveal thickness to be treated either Macugen or a sham injection. After 24 weeks, all patients will treated with Macugen until the end of the study at 54 weeks.

Official Title
-----------------
A Phase II Prospective, Randomized, Double-Masked, Sham-Controlled, Dose-Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)

Conditions
-----------------
Macular Degeneration

Intervention / Treatment
-----------------
* Drug: Macugen ™ (pegaptanib sodium injection)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Best corrected visual acuity in the study eye between 20/40 and 20/320 and better or equal to 20/800 in the fellow eye. Foveal thickness <= 300 um (measured by OCT center point thickness). Subfoveal choroidal neovascularization secondary to age-related macular degeneration, with a total lesion size (including blood, scar/atrophy & neovascularization) of <= 12 disc areas, of which at least 50% must be active CNV. Exclusion Criteria: Previous subfoveal thermal laser therapy. Any subfoveal atrophy or scarring, blood over the fovea, or fibrosis. Additionally no more than 25% of the total lesion size may be made up of scarring or atrophy. Previous photodynamic therapy with Visudyne (PDT) in the study eye. Eyes with predominantly classic lesions (as classified by fluorescein angiographic appearance) may be enrolled in the trial if, in the clinical judgment of the investigator, PDT can be deferred for at least 54 weeks after the first study treatment

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Macugen ™ (pegaptanib sodium injection)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMD, Age Related Macular Degeneration, Exudative Subfoveal Age Related Macular Degeneration with Subfoveal Choroidal Neovascularization
COVID-19 Burnout Study

Study Overview
=================
Brief Summary
-----------------
The aims of this study are to assess whether the use of a MBI therapy delivered remotely is associated with a reduction of perceived stress among HCPs in the Radiation Medicine Program (RMP) and with a decrease risk of burnout during and post COVID-19.

Official Title
-----------------
Remote Delivery of a Mindfulness-based Intervention to Decrease Anxiety Levels and Burnout Among Health-care Professionals During the Covid-19 Pandemic

Conditions
-----------------
Stress

Intervention / Treatment
-----------------
* Behavioral: Mindfulness Based Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Employee in the radiation medicine program in UHN Health Care Professional (Therapist, Nurse, Physician, Resident, Physician assistant, Physician admin assistant) Over 18 Exclusion Criteria: Not working at the radiation medicine program at UHN

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mindfulness Based Intervention<br>A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period. | Behavioral: Mindfulness Based Intervention<br>* A remotely delivered closed group mindfulness-based intervention using Microsoft Teams Meeting will be performed, consisting of 12-16 participants (Maximum 10 groups) and one professional with a background in mindfulness coaching . Three professionals will be coaching 2-3 groups each. The curriculum entails weekly sessions (1 hour) over a 4-week period.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perceived Stress | Perceived Stress measured by the Perceived Stress Scale/ Higher number indicates higher levels of stress. Minimum value = 10, Max Value = 40 | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Burnout | Burnout assessed by the 2-item Maslach Burnout Inventory using single-item measures of emotional exhaustion and depersonalization | 6 months | 
| Coping with Stress | Coping measured by the BriefCOPE questionnaire. High numbers indicate that the participant is not coping well with the specific situation. Minimum value = 28, Max Value = 112 | 6 months |
Long-Term Oral Acyclovir Usage to Prevent Herpes Zoster Virus Infection After Bone Marrow Transplant

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to prevent reactivation of herpes zoster during the first year after transplant.

Detailed Description
-----------------
Herpes zoster infection occurs in 30% of allogeneic hematopoietic cell transplant (HCT) recipients who had a history of varicella zoster virus (VZV) infection. A safe and effective prevention strategy has not been established. 77 marrow allograft recipients at risk for VZV reactivation were randomized to oral acyclovir 800 mg twice daily or placebo given from day 30 until day 365 and were followed for toxicity and clinical evidence of herpes zoster infection.

Official Title
-----------------
Randomized Trial of Long-Term Oral Acyclovir Usage to Prevent Varicella Zoster Virus Infection After Allogeneic Bone Marrow Transplant

Conditions
-----------------
VZV Infection After Bone Marrow Transplantation

Intervention / Treatment
-----------------
* Drug: Acyclovir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 10 years or older Both sex (male or female) Allogeneic transplant patient for hematologic malignancy or aplastic anemia Exclusion Criteria: Previous intolerance to acyclovir Patients who are unavailable for follow-up Patients in whom drug compliance may be a problem Evidence of active VZV infection VZV infection in the initial 1 month after transplant Pregnant women, lactating women, or those not using adequate contraception Creatinine > 3.0 mg/dl.

Ages Eligible for Study
-----------------
Minimum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Acyclovir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VZV infection at one year |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VZV infection after discontinuation of prophylaxis |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
VZV infection, Varicella Zoster Virus Infection, Oral Acyclovir, Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Cell Transplantation
A Study to Validate a New Oral Fluid/Saliva Antibody Test for Novel H1N1v Influenza

Study Overview
=================
Brief Summary
-----------------
At present influenza immunity can only be reliably confirmed by a blood test. This test is invasive for the patient. This study is intended to validate an oral fluid/saliva antibody test for the variant Swine Influenza H1N1. If such a test were available, this painless and non invasive test will improve direct clinical care to an individual as well as significantly help guide future public health management of the pandemic.

Official Title
-----------------
A Study to Validate a New Oral Fluid/Saliva Antibody Test for Novel H1N1v Influenza

Conditions
-----------------
H1N1 Virus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants of the clinical service evaluation of novel H1N1v vaccine First or second blood sample for the clinical service evaluation successfully collected Exclusion Criteria: Withdrawn from clinical service evaluation of novel H1N1v vaccine Second blood sample for the clinical service evaluation not collected.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
swine flu, novel h1n1v, novel h1n1, h1n1
The Influence of Feeding Position on Pulmonary Morbidity in Young Children

Study Overview
=================
Brief Summary
-----------------
Supine feeding position is associated with serous otitis media. The hypothesis is that supine feeding is associated with recurrent otitis media, tonsillar and adenoid hypertrophy and recurrent pneumonia secondary to recurrent aspiration.

Detailed Description
-----------------
The aim of the study is to compare two mother and child health clinic stations with similar socioeconomic background. Mothers from the study station will be instructed to feed their children only in an upright position since birth. In the control station mothers will continue to feed their children as usual. Pulmonary morbidity will be evaluated prospectively through the computer system of the insurance companies.

Official Title
-----------------
The Influence of Feeding Position on Pulmonary Morbidity in Young Children

Conditions
-----------------
Pulmonary Diseases, Tonsillar Hypertrophy, Otitis Media, Dental Caries

Intervention / Treatment
-----------------
* Behavioral: upright feeding


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newborn Mother's compliance Exclusion Criteria: Bronchopulmonary dysplasia (BPD) Asthma Cystic fibrosis Heart disease

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: upright feeding|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pulmonary and ear-throat-nose morbidity |  |  | 
| medical costs |  | measured every 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adenoid hypertrophy, feeding position, supine, upright, pneumonia, wheezing, otitis, adenoid, tonsil, caries
Mobilaser Study to Help With People Who Are Having Problems With Their Gait

Study Overview
=================
Brief Summary
-----------------
Does use of the Mobilaser reduce freezing of gait (FOG) and stride reduction in patients with Parkinson's disease and Parkinsonism.

Detailed Description
-----------------
Can patients walk faster and have less freezing when using the mobilaser then when not using it

Official Title
-----------------
Increasing Mobility in Parkinsonian Patients With Freezing of Gait and Gait Hypokinesia With an Adjustable, Attachable Laser (Mobilaser)

Conditions
-----------------
Parkinson's Disease, Parkinsonism

Intervention / Treatment
-----------------
* Device: Mobilaser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Parkinsonian patients with Freezing of Gait or Gait hesitation. Must have evidence of bradykinesia ambulating (stride reduction or reduced arm swing) Must have a constant caregiver Exclusion Criteria: No cardiopulmonary contraindications to ambulation, e.g., unstable angina pectoris; Severe arthritis; Cerebellar or sensory ataxia; Recent knee or hip surgery

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mobilaser<br>Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference. | Device: Mobilaser<br>* Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.<br>* Other names: Walker with laser;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in Gait |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's disease, Parkinsonism, Gait problems, Freezing gait
A Random Selection of Patients From the SENTRY Study Who Have a Bioconverted Sentry IVC Filter in Situ With a Minimum Dwell Time of 24 Months From a Single Center Follow up

Study Overview
=================
Brief Summary
-----------------
IVUS Evaluation of the Bioabsorbable Sentry IVC Filter 3-5 Years Post Deployment Follow up

Detailed Description
-----------------
IVUS Evaluation of the Bioabsorbable Sentry IVC Filter 3-5 Years Post Deployment Follow up

Official Title
-----------------
A Random Selection of Patients From the SENTRY Study Who Have a Bioconverted Sentry IVC Filter in Situ With a Minimum Dwell Time of 24 Months From a Single Center

Conditions
-----------------
Recurrent Pulmonary Embolism (Disorder)

Intervention / Treatment
-----------------
* Diagnostic Test: IVUS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age Signed the informed consent document Participants from the SENTRY clinical trial willing to undergo one time IVUS evaluation ( outpatient ) Exclusion Criteria: Any filter that remained non converted.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: IVUS|IVUS|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patency of the inferior vena cava |  | 3-5 years | 
| Cylindrical frame integrity | Cylindrical frame integrity | 3-5 years | 
| Impact of the Sentry cylindrical frame on the vessel wall evaluation for endothelialization and neointimal hyperplasia and wall dynamics | Impact of the Sentry cylindrical frame on the vessel wall evaluation for endothelialization and neointimal hyperplasia and wall dynamics | 3-5 years | 
| Presence and characterization of adherent thrombus | Presence and characterization of adherent thrombus | 3-5 years |
A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients

Study Overview
=================
Brief Summary
-----------------
The primary goal of this study is to identify a gene or panel of genes which are differentially expressed in lung cells and tissue from asthmatic patients following administration of Ipratropium bromide and eiTher nebulised Albuterol or saline. Each subject in this study will undergo two bronchoscopies.

Official Title
-----------------
A Study to Identify a Transcriptomic Profile Indicative of Cycle AMP Pathway Activation in the Lung

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Have a history of intermittant asthma. Have asthma symptoms less than once per week. Have no other significant disease. Do not take regular oral or inhaled steroids. Are a non-smoker for the past 12 months with a pack history of less than 5 years. Exclusion criteria: Have a history of drug or alcohol abuse. Have poorly controlled asthma or a history of life-threatening asthma. Have a history of hypersensitivity to bronchodilators. Are unable to abstain from inhaled steroids from 14 days prior to the first study visit until completion of the study. Have received oral steroids within 3 months of study entry. Have been hospitalized for your asthma within 3 months of study entry. Have had treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma bronchoscopy
The Acute Effect of Statins on Inflammatory Markers of Athersclerotic Tissue

Study Overview
=================
Brief Summary
-----------------
This study is being done to determine if the acute administration of the drug Simvastatin reduces plaque tissue inflammation and plaque instability in patients undergoing carotid endarectomy

Official Title
-----------------
The Acute Effect of Inflammatory Markers of Atherosclerotic Plaque in Humans

Conditions
-----------------
Carotid Artery Disease

Intervention / Treatment
-----------------
* Drug: simvastatin
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing carotid endarterectomy No previously known side effects of statins Patients who will sign an informed consent Age > 18 years old No signs of current infection Exclusion Criteria: Patient hypersensitive to any component of this medication Patients with acute liver disease (AST> normal value) Patients with chronic liver disease (history of Hepatitis B or C) Patients with renal failure (creatinine > 3.0) Patients with unexplained muscle pains and aches Patients with rheumatoid arthritis Patients with Lupus Current cancer treatment Patients on cyclosporin, digoxin, Itraconazole, Ketoconazole and other antifungal azoles, the macrolide antibiotics and antidepressant nefazodone Pregnant females

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Two 80 mg pills simvastatin taken 24 hours prior to surgery | Drug: simvastatin<br>* Two 80 mg pills simvastatin taken 24 hours prior to surgery<br>* Other names: Zocor;|
| Placebo Comparator: 2<br>Two 80 mg pills placebo are taken 24 hours prior to surgery | Drug: placebo<br>* take 2 80 mg pills placebo 24 hours prior to surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| This study is being done to see if giving the study drug, Simvastatin, quickly lessens the swelling of plaque tissue (tissue around your heart) and plaque movement in patients undergoing cqrotid endarterectomy procedure. |  | 24 prior to surgery |
Detection of Helicobacter Pylori in Ulcerative Colitis Patients

Study Overview
=================
Brief Summary
-----------------
Helicobacter pylori (H. pylori) infection is one of the most common infectious diseases in humans.

Detailed Description
-----------------
Several bacterial and viral agents may have a role in the aetiology of IBD. In theory, H. pylori infection could be involved in IBD by inducing alterations in gastric and/or intestinal permeability or by causing immunological derangements resulting in absorption of antigenic material and autoimmunity via various immunological pathways.

Official Title
-----------------
Detection of Helicobacter Pylori in Colonic Tissue in Newly Diagnosed Ulcerative Colitis Patients

Conditions
-----------------
Inflammatory Bowel Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: Colonoscopy and biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: newly diagnosed ulcerative colitis Exclusion Criteria: Other diagnosis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Colonoscopy and biopsy<br>IBD patients | Diagnostic Test: Colonoscopy and biopsy<br>* Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.<br>|
| No Intervention: Colonoscopic biopsy<br>Non IBD patients colonoscopic biopsy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with Helicobacter | Number of patients with Helicobacter | 6 months |